Autonomix Medical secures US patent on feedback-guided neuromodulation

Autonomix Medical (NASDAQ: AMIX) has been granted US Patent No. 12,714,780 by the United States Patent and Trademark Office, covering systems that integrate real-time physiological feedback, sensing and imaging with controlled therapeutic delivery. The patent, issued on 25 August 2026, is titled "Systems and Methods for Regulating Organ and/or Tumour Growth Rates, Function, and/or Development" and extends the Texas-based medical device company's intellectual property position in the precision neuromodulation space.

The newly granted patent covers surgical systems that use physiological feedback signals from a targeted tissue region to regulate treatment delivery, including the controlled administration of therapeutic fluid. Notably, it encompasses applications in which the targeted tissue is a tumour and the therapeutic fluid is configured to effect neural ablation to reduce cancer-related pain. The patent also covers the use of denervating agents and neuroblocking agents, with described applications across organs of the lower urinary tract, hormone secretion and organ function.

What the patent covers

Brad Hauser, chief executive of Autonomix Medical, said the patent "reflects the potential of our technology platform to combine sensing, imaging and targeted therapy delivery to enable more controlled and personalised interventions." The company is positioning the intellectual property as a foundational layer for its broader neuromodulation platform, which includes a catheter-based microchip sensing array designed to detect and differentiate neural signals transvascularly.

The patent traces back to continuation applications originally filed in 2012 and 2014, underlining that the core technology has been in development for over a decade. Autonomix's lead clinical focus is pancreatic cancer pain, for which the company says current treatment options remain inadequate. The technology remains investigational and has not been cleared for marketing by the US Food and Drug Administration.

Market context and competitive landscape

Patent portfolio expansion is a common signalling mechanism for early-stage medical device companies seeking to reinforce platform credibility with investors and potential partners ahead of clinical milestones. Autonomix's neuromodulation approach sits within a broader and increasingly active field. Established players such as Abbott, Medtronic and Boston Scientific hold substantial positions in neuromodulation, largely in spinal cord stimulation and deep brain stimulation, while a number of smaller companies are pursuing catheter-based and transvascular nerve-targeting approaches for visceral pain and autonomic disorders.

The pancreatic cancer pain indication is clinically unmet and commercially attractive, but also technically demanding. Neural ablation via a transvascular route is a high-complexity intervention, and regulatory clearance will require robust safety and efficacy data from well-controlled trials. The company has not yet disclosed a timeline or design for a pivotal study.

For investors, the patent grant is a non-dilutive positive that shores up freedom to operate, though it does not advance the clinical programme directly. Attention will remain focused on when Autonomix moves beyond its early-stage trials and into a more formal regulatory pathway with the FDA. The breadth of applications described in the patent, spanning oncology pain, urology and cardiology, may also attract licensing or partnership interest as the platform matures.